Trial Profile
A phase I/II trial of sapacitabine in combination with other agents for the treatment of myelodysplastic syndromes
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 15 Jan 2016
Price :
$35
*
At a glance
- Drugs Sapacitabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 15 Jan 2016 New trial record
- 11 Jan 2016 According to a Cyclacel Pharmaceuticals media release, this trial is expected to start in 2016.